Trial Profile
A randomised mulitcentre trial of tenofovir (TDF) vs lamividine (LAM) vs TDF/LAM in antiretroviral naive subjects with HIV/HBV conifection over 48 weeks.
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 26 Nov 2019
Price :
$35
*
At a glance
- Drugs Tenofovir (Primary) ; Lamivudine
- Indications Hepatitis B; HIV-1 infections
- Focus Therapeutic Use
- Acronyms TICO
- 08 Jun 2016 Status changed from recruiting to completed.
- 14 Jul 2011 New trial record